Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · U.S. Code · Title 21 - FOOD AND DRUGS · CHAPTER 13— DRUG ABUSE PREVENTION AND CONTROL · SUBCHAPTER I— CONTROL AND ENFORCEMENT · § 814

§ 814. Removal of exemption of certain drugs

849 words·~4 min read·/usc/title-21/section-814

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Removal of exemption The Attorney General shall by regulation remove from exemption under section 802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.
(b)Factors to be considered In removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—
(1)the scope, duration, and significance of the diversion;
(2)whether the drug or group of drugs is formulated in such a way that it cannot be easily used in the illicit production of a controlled substance; and
(3)whether the listed chemical can be readily recovered from the drug or group of drugs.
(c)Specificity of designation The Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection
(a)to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of diversion and other relevant factors, that the diversion will not be limited to that particular drug or group of drugs.
(d)Reinstatement of exemption with respect to particular drug products
(1)Reinstatement On application by a manufacturer of a particular drug product that has been removed from exemption under subsection (a), the Attorney General shall by regulation reinstate the exemption with respect to that particular drug product if the Attorney General determines that the particular drug product is manufactured and distributed in a manner that prevents diversion.
(2)Factors to be considered In deciding whether to reinstate the exemption with respect to a particular drug product under paragraph (1), the Attorney General shall consider—
(A)the package sizes and manner of packaging of the drug product;
(B)the manner of distribution and advertising of the drug product;
(C)evidence of diversion of the drug product;
(D)any actions taken by the manufacturer to prevent diversion of the drug product; and
(E)such other factors as are relevant to and consistent with the public health and safety, including the factors described in subsection
(b)as applied to the drug product.
(3)Status pending application for reinstatement A transaction involving a particular drug product that is the subject of a bona fide pending application for reinstatement of exemption filed with the Attorney General not later than 60 days after a regulation removing the exemption is issued pursuant to subsection
(a)shall not be considered to be a regulated transaction if the transaction occurs during the pendency of the application and, if the Attorney General denies the application, during the period of 60 days following the date on which the Attorney General denies the application, unless—
(A)the Attorney General has evidence that, applying the factors described in subsection
(b)to the drug product, the drug product is being diverted; and
(B)the Attorney General so notifies the applicant.
(4)Amendment and modification A regulation reinstating an exemption under paragraph
(1)may be modified or revoked with respect to a particular drug product upon a finding that—
(A)applying the factors described in subsection
(b)to the drug product, the drug product is being diverted; or
(B)there is a significant change in the data that led to the issuance of the regulation.
(Pub. L. 91–513, title II, § 204, as added Pub. L. 103–200, § 2(b)(1), Dec. 17, 1993, 107 Stat. 2334; amended Pub. L. 104–237, title IV, § 401(c), Oct. 3, 1996, 110 Stat. 3108; Pub. L. 109–177, title VII, § 712(a)(2), Mar. 9, 2006, 120 Stat. 263.)
Connections19 cite this · traces to 1
11 references not yet in our index
  • Pub. L. 91–513, title II, § 204
  • Pub. L. 103–200, § 2(b)(1)
  • 107 Stat. 2334
  • Pub. L. 104–237, title IV, § 401(c)
  • 110 Stat. 3108
  • Pub. L. 109–177, title VII, § 712(a)(2)
  • 120 Stat. 263
  • Pub. L. 109–177
  • Pub. L. 104–237
  • section 401(g) of Pub. L. 104–237
  • section 11 of Pub. L. 103–200
Citation graph
cites case law
§ 814
Removal of exemption of certain drugs
Fed. Reg.×9
U.S.C.×5
Stat. Comp.×2
Stat.×2
Bills×1
Pub. L.Pub. L. 91–513, title II, § 204
Pub. L.Pub. L. 103–200, § 2(b)(1)
Stat.107 Stat. 2334
Pub. L.Pub. L. 104–237, title IV, § 401(c)
Stat.110 Stat. 3108
Cites 12 · showing 6Cited by 19 across 5 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.